IQ-AI’s Imaging Biometrics Seeks FDA Breakthrough Designation for GaM Therapy

 

IQ-AI Limited (LSE:IQAI) has announced that its subsidiary, Imaging Biometrics, has applied for the FDA’s Breakthrough Therapy Designation for its oral gallium maltolate (GaM) therapy. The therapy is being developed for the treatment of recurrent or refractory glioblastoma (GBM) IDH-wildtype. Early results from the Phase 1 trial show a promising overall survival rate of 34.1 months, a significant improvement compared to the median of 14-15 months for standard treatments. If granted, the Breakthrough Therapy Designation would provide the company with more intensive guidance and support from the FDA, potentially enhancing its market position and offering renewed hope for more effective GBM treatments.

About IQ-AI Limited

Imaging Biometrics, LLC, a wholly-owned subsidiary of IQ-AI Limited, specializes in quantitative imaging platforms and therapeutics. The company is dedicated to enhancing clinical diagnosis and treatment efficiency, aiming to improve the effectiveness of medical interventions.

• Year-to-Date Price Performance: -38.21%

• Average Trading Volume: 626,352 shares

• Technical Sentiment Signal: Strong Buy

• Market Capitalization: £2.13 million

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Robbie Burns

• 

  Luca Rossi

• 

  Tom Frew

• 

  Alexander Evagora